Overview
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Description
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.
Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.
All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.
Eligibility
Inclusion Criteria:
- Diagnosed as AML after 1 Jan 2020
- Patients signed informed consent form
Exclusion Criteria:
- Patients under 18 years old